title: Multi-target parallel processing approach for gene-to-structure determination of the influenza polymerase PB2 subunit.
abstract: Pandemic outbreaks of highly virulent influenza strains can cause widespread morbidity and mortality in human populations worldwide. In the United States alone, an average of 41,400 deaths and 1.86 million hospitalizations are caused by influenza virus infection each year (1). Point mutations in the polymerase basic protein 2 subunit (PB2) have been linked to the adaptation of the viral infection in humans (2). Findings from such studies have revealed the biological significance of PB2 as a virulence factor, thus highlighting its potential as an antiviral drug target. The structural genomics program put forth by the National Institute of Allergy and Infectious Disease (NIAID) provides funding to Emerald Bio and three other Pacific Northwest institutions that together make up the Seattle Structural Genomics Center for Infectious Disease (SSGCID). The SSGCID is dedicated to providing the scientific community with three-dimensional protein structures of NIAID category A-C pathogens. Making such structural information available to the scientific community serves to accelerate structure-based drug design. Structure-based drug design plays an important role in drug development. Pursuing multiple targets in parallel greatly increases the chance of success for new lead discovery by targeting a pathway or an entire protein family. Emerald Bio has developed a high-throughput, multi-target parallel processing pipeline (MTPP) for gene-to-structure determination to support the consortium. Here we describe the protocols used to determine the structure of the PB2 subunit from four different influenza A strains.
authors.affiliation: Protein Crystallization Lab, Emerald Bio.
authors.forename: Brianna L
authors.initials: BL
authors.lastname: Armour
authors.forename: Steve R
authors.initials: SR
authors.lastname: Barnes
authors.forename: Spencer O
authors.initials: SO
authors.lastname: Moen
authors.forename: Eric
authors.initials: E
authors.lastname: Smith
authors.forename: Amy C
authors.initials: AC
authors.lastname: Raymond
authors.forename: James W
authors.initials: JW
authors.lastname: Fairman
authors.forename: Lance J
authors.initials: LJ
authors.lastname: Stewart
authors.forename: Bart L
authors.initials: BL
authors.lastname: Staker
authors.forename: Darren W
authors.initials: DW
authors.lastname: Begley
authors.forename: Thomas E
authors.initials: TE
authors.lastname: Edwards
authors.forename: Donald D
authors.initials: DD
authors.lastname: Lorimer
mesh_terms: D018360:Crystallography, X-Ray; D023281:Genomics / Q000379:methods; D053118:Influenza A Virus, H1N1 Subtype / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D053122:Influenza A Virus, H3N2 Subtype / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D053124:Influenza A Virus, H5N1 Subtype / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D008958:Models, Molecular; D017433:Protein Structure, Secondary; D021122:Protein Subunits; D012324:RNA-Dependent RNA Polymerase / Q000737:chemistry* / Q000235:genetics*; D014764:Viral Proteins / Q000737:chemistry* / Q000235:genetics*
chemical_list: C057027:PB2 protein, Influenzavirus A; D021122:Protein Subunits; D014764:Viral Proteins; D012324:RNA-Dependent RNA Polymerase